By Amy Siegel, S2N Health For the past few years, medtech entrepreneurs have seemed practically apologetic for being in medtech. True, there are many reasons, or maybe excuses, to have had ears down and tail between legs. Venture capital has generally favored biotech and health IT over medtech. The large medical device companies have been more focused […]
The Business of Emerging Medtech
The drug pricing backlash – Should medtech pay attention?
By Amy Siegel, S2N Health Admittedly, the biotech boom of the past few years has left some of us in medtech feeling a bit inferior, maybe even jealous. Those huge funding rounds, heady IPOs and rich pre-revenue M&A deals can be hard to swallow, especially when investors keep asking you why you can’t be more […]
Five tall tales medtech startups tell investors
By Amy Siegel, S2N Health Honesty is a virtue to which we all aspire, but in the game of funding a medtech startup sometimes the straight story and a nickel won’t buy you a cup of coffee. Most entrepreneurs, particularly the engineering types who tend to invent medical devices, aren’t deliberate fib-tellers. They are passionate about their innovations, confident […]
Skin in the game: Can risk sharing energize medtech?
The Pfizer-Hospira Deal: Do Pharma and Device Companies Need Each Other?

Having been at the flag-raising ceremony for Hospira when it spun out of Abbott back in 2004, the news of Pfizer’s acquisition was a bit emotional for me. I didn’t cry or anything, but I did feel a little sad, and a little proud, and maybe a little hopeful at the end of the day.
Medtech M&A: Tips from the front lines

S2N recently hosted an informal gathering of emerging med tech CEOs, a sort of group therapy session for people suffering from the form of temporary insanity that makes one want to be a healthcare entrepreneur.